CLLS

Cellectis ADR

0.9750

Oct 22 • 3:59 PM ET +0.0065 (0.67%)

0.9750

Aftermarket • 4:15 PM ET 0.0000 (0.00%)

Healthcare Biotechnology France Micro NASD

Peers: CRBU ALLO ATRA CRSP DTIL IPSC SANA FATE NKTX AUTL

| Held by: IBB

Scroll to Statements

Index	-
Market Cap	70.52M
Enterprise Value	7.95M
Income	-65.33M
Sales	56.42M
Book/sh	0.41
Cash/sh	2.31
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	229
IPO	Mar 25, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	1.25
P/B	2.39
P/C	0.42
P/FCF	-
EV/EBITDA	-
EV/Sales	0.14
Quick Ratio	1.37
Current Ratio	1.37
Debt/Eq	2.54
LT Debt/Eq	2.19
Option/Short	Yes / Yes

EPS (ttm)	-0.65
EPS next Y	-0.67
EPS next Q	-0.18
EPS this Y	-19.90%
EPS next Y	17.01%
EPS next 5Y	-26.03%
EPS past 3/5Y	33.81% 18.84%
Sales past 3/5Y	56.25% -0.34%
EPS Y/Y TTM	-13.99%
Sales Y/Y TTM	-0.11%
EPS Q/Q	9.72%
Sales Q/Q	-69.19%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	16.35% -37.52%

Insider Own	3.93%
Insider Trans	0.00%
Inst Own	13.18%
Inst Trans	0.30%
ROA	-21.03%
ROE	-94.56%
ROIC	-49.84%
Gross Margin	66.25%
Oper. Margin	-116.10%
Profit Margin	-115.79%
SMA20	-21.45%
SMA50	-54.42%
SMA200	-69.22%
Trades

Shs Outstand	100.70M
Shs Float	69.48M
Short Float	0.51%
Short Ratio	3.60
Short Interest	0.35M
52W High	5.45 -82.11%
52W Low	0.88 10.69%
Volatility	12.15% 7.53%
ATR (14)	0.12
RSI (14)	23.09
Beta	3.15
Rel Volume	1.33
Avg Volume	97.47K
Volume	129,354

Perf Week	-11.76%
Perf Month	-32.29%
Perf Quarter	-65.67%
Perf Half Y	-75.06%
Perf YTD	-79.86%
Perf Year	-72.84%
Perf 3Y	-19.42%
Perf 5Y	-90.95%
Perf 10Y	-94.87%
Recom	2.29
Target Price	5.00
Prev Close	0.97
Price	0.98
Change %	0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-16-26	Downgrade	Barclays	Overweight → Underweight	$1.30
Sep-15-26	Downgrade	Citizens	Mkt Outperform → Mkt Perform
May-28-26	Initiated	Barclays	Overweight	$9
Feb-17-26	Resumed	Jefferies	Buy	$7
Mar-17-23	Initiated	Bryan Garnier	Buy	$6
May-18-22	Upgrade	Robert W. Baird	Neutral → Outperform	$10
Jan-06-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$39 → $16
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$20
Nov-08-21	Downgrade	William Blair	Outperform → Mkt Perform
Oct-08-21	Downgrade	Robert W. Baird	Outperform → Neutral	$39 → $10
Apr-28-21	Downgrade	Guggenheim	Buy → Neutral
Mar-16-21	Upgrade	Robert W. Baird	Neutral → Outperform	$23 → $39
Aug-19-20	Upgrade	Citigroup	Neutral → Buy	$15 → $32
May-12-20	Initiated	Robert W. Baird	Outperform	$20
Mar-06-20	Downgrade	Goldman	Neutral → Sell	$15 → $11
Oct-30-19	Resumed	Guggenheim	Buy	$28
Aug-09-19	Initiated	BTIG Research	Buy	$37
May-24-19	Resumed	Citigroup	Neutral	$22
Mar-14-19	Initiated	William Blair	Outperform
Dec-19-18	Initiated	Goldman	Neutral

Show Previous Ratings

Oct-06-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-16-26 09:42AM	Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls (The Fly) -14.60%
Sep-15-26 09:35AM	Ulta Beauty, Etsy upgraded: Wall Street's top analyst calls (The Fly) -12.02%
07:11AM	CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot (Stocktwits)
Sep-14-26 10:41AM	Cellectis Announces In Vivo Gene Editing Transformation, Exits Lasme-cel and Eti-cel Development (InvestorsHub) -40.97%
07:46AM	Loading…
07:46AM	Cellectis quits CAR-Ts and pivots to in vivo gene editing (BioPharma Dive)
07:46AM	Cellectis quits CAR-T and pivots to in vivo gene editing (BioPharma Dive)
02:40AM	Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company (GlobeNewswire)
Sep-11-26 04:30PM	Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update (GlobeNewswire)
Sep-03-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-01-26 04:30PM	Cellectis Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-06-26 04:30PM	Cellectis Reports Financial Results for the Second Quarter 2026 (GlobeNewswire) +5.39%
Aug-05-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jul-30-26 04:30PM	Cellectis to Report Second Quarter Financial Results on August 6, 2026 (GlobeNewswire)
Jul-02-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +12.24%
04:30PM	Loading…
Jun-25-26 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 (GlobeNewswire)
Jun-11-26 02:40AM	Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress (GlobeNewswire)
Jun-09-26 06:30PM	CLLS Stock Rallies Over 24% After Hours Here's Why (Stocktwits) +6.35%
04:30PM	Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL (GlobeNewswire)
Jun-03-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -8.58%
May-28-26 11:26AM	Barclays initiates oncology-focused biotechs with positive outlook (Investing.com)
May-20-26 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026 (GlobeNewswire)
May-12-26 09:30AM	Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress (GlobeNewswire)
May-11-26 04:30PM	Cellectis Reports Financial Results for the First Quarter 2026 (GlobeNewswire)
May-06-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.05%
May-04-26 04:30PM	Cellectis to Report First Quarter Financial Results on May 11, 2026 (GlobeNewswire) -6.33%
Apr-27-26 04:30PM	Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting (GlobeNewswire)
Apr-13-26 04:30PM	Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform (GlobeNewswire) +19.22%
Apr-07-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.65%
Mar-20-26 03:00PM	Cellectis SA (CLLS) Q4 2025 Earnings Call Highlights: Promising Clinical Progress and Strategic ... (GuruFocus.com)
07:21PM	Loading…
Mar-19-26 07:21PM	Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update (GlobeNewswire)
09:17AM	What To Expect From Cellectis SA (XPAR:ALCLS) Q4 2025 Earnings (GuruFocus.com)
Mar-12-26 04:30PM	Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 (GlobeNewswire) -12.37%
03:33AM	Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board (Proactive)
Mar-04-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-04-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-08-26 04:30PM	Cellectis Announces 2026 Strategy and Catalysts (GlobeNewswire)
Jan-05-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -5.42%
Dec-15-25 04:51PM	Cellectis Announces Arbitral Decision in Dispute with Servier (GlobeNewswire) -15.24%
Dec-08-25 01:30AM	ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL (GlobeNewswire)
Dec-03-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-19-25 06:18AM	Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells (GlobeNewswire) +7.06%
Nov-07-25 04:30PM	Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +11.29%
11:30AM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-03-25 09:15AM	Cellectis to Present a Development Update for eti-cel at ASH 2025 (GlobeNewswire) -5.22%
Oct-31-25 04:30PM	Cellectis to Report Third Quarter Financial Results on November 7, 2025 (GlobeNewswire)
Oct-16-25 03:19PM	Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL (GlobeNewswire) +9.98%
07:00AM	Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers (GlobeNewswire)
Oct-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +8.22% +12.57%
02:40AM	Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress (GlobeNewswire)
Sep-03-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-04-25 04:30PM	Cellectis Reports Second Quarter 2025 Financial Results & Business Updates (GlobeNewswire) -16.23%
10:04AM	Earnings To Watch: Cellectis SA (CLLS) Reports Q2 2025 Result (GuruFocus.com)
Jul-28-25 04:30PM	Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025 (GlobeNewswire) +13.10%
Jul-04-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-26-25 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 (GlobeNewswire)
Jun-05-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-21-25 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025 (GlobeNewswire)
May-12-25 04:30PM	Cellectis Reports Financial Results for the First Quarter 2025 (GlobeNewswire) -6.62%
May-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-06-25 04:30PM	Cellectis to Report First Quarter Financial Results on May 12, 2025 (GlobeNewswire)
Apr-28-25 04:30PM	Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting (GlobeNewswire)
Apr-22-25 09:00AM	Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal (MarketBeat)
Apr-21-25 05:02PM	Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... (GuruFocus.com)
Apr-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.00%
Mar-13-25 06:07PM	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update (GlobeNewswire)
Mar-07-25 04:30PM	Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 (GlobeNewswire)
Mar-06-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-24-25 01:30AM	Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 (GlobeNewswire)
Feb-04-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-28-25 08:00AM	Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer (GlobeNewswire)
Jan-08-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -8.10%
Jan-07-25 11:28AM	Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't? (Zacks)
Dec-29-24 08:24AM	Analysts Predict 400% Upside Potential for This Penny Stock (GuruFocus.com)
Dec-10-24 04:30PM	Cellectis announces the drawdown of the third tranche of 5 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire)
Dec-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-06-24 04:38PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-05-24 04:30PM	Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting (GlobeNewswire)
Nov-04-24 04:30PM	Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 (GlobeNewswire)
07:14AM	What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings (GuruFocus.com)
Oct-30-24 04:30PM	Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 (GlobeNewswire)
Oct-23-24 06:29AM	Cellectis Presents New Gene-Editing Breakthroughs (TipRanks) +9.44%
Oct-22-24 02:00AM	Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress (GlobeNewswire)
Oct-02-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-03-24 04:30PM	Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety (GlobeNewswire) -5.83%
Aug-26-24 04:30PM	Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors (GlobeNewswire)
Aug-07-24 02:00AM	Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer (GlobeNewswire)
Aug-06-24 04:30PM	Cellectis Provides Financial Results for the Second Quarter 2024 (GlobeNewswire)
Aug-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-02-24 09:53AM	Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia (Pharmaceutical Technology)
Aug-01-24 04:30PM	FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment (GlobeNewswire)
Jul-25-24 04:30PM	FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment (GlobeNewswire) +12.20%
Jul-10-24 09:35AM	Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS) (Zacks)
Jul-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-28-24 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 (GlobeNewswire)
Jun-20-24 04:30PM	Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing (GlobeNewswire)
Jun-18-24 12:00PM	Cellectis (CLLS) Upgraded to Buy: Here's Why (Zacks) -5.84%
09:35AM	After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS) (Zacks)

Show Previous News

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.

Co-FounderDr. Andre Choulika Ph.D.

Co-FounderDr. David J. Sourdive Ph.D.

CFO & Chief Business OfficerMr. Arthur Stril

Principal Financial Officer & Principal Accounting OfficerValerie Cros

Chief Technological OfficerMr. Jean Charles Epinat Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLLS

Cellectis ADR

Upgrade your Finviz experience